Search Results - "SIRTORI, Cesare"

Refine Results
  1. 1

    The pharmacology of statins by Sirtori, Cesare R.

    Published in Pharmacological research (01-10-2014)
    “…Statins, inhibitors of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase enzyme, are molecules of fungal origin. By inhibiting a key step in the sterol…”
    Get full text
    Journal Article
  2. 2

    PPAR Agonists and Metabolic Syndrome: An Established Role? by Botta, Margherita, Audano, Matteo, Sahebkar, Amirhossein, Sirtori, Cesare R, Mitro, Nico, Ruscica, Massimiliano

    “…Therapeutic approaches to metabolic syndrome (MetS) are numerous and may target lipoproteins, blood pressure or anthropometric indices. Peroxisome…”
    Get full text
    Journal Article
  3. 3

    Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications by Ruscica, Massimiliano, Ferri, Nicola, Banach, Maciej, Sirtori, Cesare R, Corsini, Alberto

    Published in Cardiovascular research (18-01-2023)
    “…Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, has proven beneficial preventive effects on cardiovascular events…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    PCSK9 inhibition and inflammation: A narrative review by Ruscica, Massimiliano, Tokgözoğlu, Lale, Corsini, Alberto, Sirtori, Cesare R.

    Published in Atherosclerosis (01-09-2019)
    “…Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality despite excellent pharmacological and revascularization…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Clinical approach to the inflammatory etiology of cardiovascular diseases by Ruscica, Massimiliano, Corsini, Alberto, Ferri, Nicola, Banach, Maciej, Sirtori, Cesare R.

    Published in Pharmacological research (01-09-2020)
    “…[Display omitted] Inflammation is an obligatory marker of arterial disease, both stemming from the inflammatory activity of cholesterol itself and from…”
    Get full text
    Journal Article
  9. 9

    The Role of High-Density Lipoprotein Cholesterol in 2022 by Sirtori, Cesare R., Corsini, Alberto, Ruscica, Massimiliano

    Published in Current atherosclerosis reports (01-05-2022)
    “…Purpose of the Review High-density lipoproteins (HDL) are responsible for the transport in plasma of a large fraction of circulating lipids, in part from…”
    Get full text
    Journal Article
  10. 10

    Bempedoic Acid: for Whom and When by Ruscica, Massimiliano, Sirtori, Cesare R., Carugo, Stefano, Banach, Maciej, Corsini, Alberto

    Published in Current atherosclerosis reports (01-10-2022)
    “…Purpose of Review The aim of creating an orally active non-statin cholesterol-lowering drug was achieved with bempedoic acid, a small linear molecule providing…”
    Get full text
    Journal Article
  11. 11

    Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia by Ruscica, Massimiliano, Zimetti, Francesca, Adorni, Maria Pia, Sirtori, Cesare R., Lupo, Maria Giovanna, Ferri, Nicola

    Published in Pharmacological research (01-03-2020)
    “…[Display omitted] Among the determinants of atherosclerotic cardiovascular disease (ASCVD), genetic and experimental evidence has provided data on a major role…”
    Get full text
    Journal Article
  12. 12

    Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches by Dongiovanni, Paola, Paolini, Erika, Corsini, Alberto, Sirtori, Cesare R., Ruscica, Massimiliano

    Published in European journal of clinical investigation (01-07-2021)
    “…Background A consensus of experts has proposed to replace the term nonalcoholic fatty liver disease (NAFLD), whose global prevalence is 25%, with metabolic…”
    Get full text
    Journal Article
  13. 13

    Unravelling the health effects of fasting: a long road from obesity treatment to healthy life span increase and improved cognition by Wilhelmi de Toledo, Françoise, Grundler, Franziska, Sirtori, Cesare R., Ruscica, Massimiliano

    Published in Annals of medicine (Helsinki) (03-07-2020)
    “…In recent years a revival of interest has emerged in the health benefits of intermittent fasting and long-term fasting, as well as of other related nutritional…”
    Get full text
    Journal Article
  14. 14

    Lipoprotein(a): Knowns, unknowns and uncertainties by Ruscica, Massimiliano, Sirtori, Cesare R., Corsini, Alberto, Watts, Gerald F., Sahebkar, Amirhossein

    Published in Pharmacological research (01-11-2021)
    “…Over the last 10 years, there have been advances on several aspects of lipoprotein(a) which are reviewed in the present article. Since the standard…”
    Get full text
    Journal Article
  15. 15

    Metformin: From diabetes to cancer to prolongation of life by Sirtori, Cesare R., Castiglione, Sofia, Pavanello, Chiara

    Published in Pharmacological research (01-10-2024)
    “…The metformin molecule dates back to over a century, but its clinical use started in the ‘50s. Since then, its use in diabetics has grown constantly, with over…”
    Get full text
    Journal Article
  16. 16

    PCSK9 Inhibition and Risk of Diabetes: Should We Worry? by Carugo, Stefano, Sirtori, Cesare R., Corsini, Alberto, Tokgozoglu, Lale, Ruscica, Massimiliano

    Published in Current atherosclerosis reports (01-12-2022)
    “…Purpose of Review Since the clinical benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors occurs in a setting of reducing low-density…”
    Get full text
    Journal Article
  17. 17

    Lipid Lowering Drugs: Present Status and Future Developments by Ruscica, Massimiliano, Ferri, Nicola, Santos, Raul D., Sirtori, Cesare R., Corsini, Alberto

    Published in Current atherosclerosis reports (10-03-2021)
    “…Purpose of review Based on the recent data of the DA VINCI study, it is clear that, besides utilization of statins, there is a need to increase non-statin…”
    Get full text
    Journal Article
  18. 18

    Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9 by Ferri, Nicola, Ruscica, Massimiliano, Lupo, Maria Giovanna, Vicenzi, Marco, Sirtori, Cesare R., Corsini, Alberto

    Published in Pharmacological research (01-10-2022)
    “…Immediate and aggressive lipid lowering therapies after acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI) are supported by the…”
    Get full text
    Journal Article
  19. 19

    Present therapeutic role of cholesteryl ester transfer protein inhibitors by Ferri, Nicola, Corsini, Alberto, Sirtori, Cesare R., Ruscica, Massimiliano

    Published in Pharmacological research (01-02-2018)
    “…[Display omitted] Therapeutic interventions aimed at increasing high-density lipoprotein (HDL) levels in order to reduce the residual cardiovascular (CV) risk…”
    Get full text
    Journal Article
  20. 20